- 503Pharma
- Posts
- 503Pharma Weekly Compounding Pharmacy Roundup
503Pharma Weekly Compounding Pharmacy Roundup
Your trusted source for compounding pharmacy education, news and insights.
503Pharma .
August 20, 2026
STABILITY STUDY CONSORTIUM — FOUNDING MEMBER SPOTS
The 503Pharma Group Stability Study Consortium launches with 20 founding seats at $4,000/year. Membership includes three Category 3 stability studies and extended BUD data you can reference. A single solo study costs more than the full membership.
$4,000/year for at least 3 studies
Limited to 20 founding members
This is the lowest price this program will ever be
See the details and FAQs → or reply to this email and we’ll send enrollment details.
This Week's Headlines
MANUFACTURER LITIGATION
Lilly Files Six Lawsuits Over Unapproved Retatrutide
Eli Lilly sued six U.S. sellers of unapproved retatrutide on August 12, including one compounding pharmacy — Striker Pharmacy, LLC (S.D. Tex.). The others are four research-use-only peptide vendors and a California med spa. These are civil complaints, not judgments, and not an FDA action.
Lilly's release says retatrutide remains in Phase 3 and that "no medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world." They have referred more than 200 individuals and entities to regulators and flagged more than 14,000 listings in more than 100 countries. .
Defendant | Court | CBS characterization |
|---|---|---|
Aesthetic Envy Cosmetic Centers LLC d/b/a Aesthetic Envy | N.D. Cal. | California med spa |
Astra LLC d/b/a Astra Peptides | W.D. Tex. | RUO peptide vendor |
Legendary Peptides, LLC | E.D. Tex. | RUO peptide vendor |
Striker Pharmacy, LLC | S.D. Tex. | Compounding pharmacy |
Texas Peptides Inc. | W.D. Tex. | RUO peptide vendor |
Lone Star Peptide Co. | S.D. Tex. | RUO peptide vendor |
GLP-1 LITIGATION
Court Lets Lilly’s State-Law “New Drug” Claims Against Revive Rx Proceed
Judge Lee Rosenthal (S.D. Tex., No. H-23-3521) denied Revive Rx’s motion for judgment on the pleadings on August 4, letting Lilly’s unfair-competition claims proceed under seven states’ laws. The holding: a compounded combination such as tirzepatide with vitamin B6 can be an unapproved “new drug” under state law regardless of who compounded it or whether a prescription was involved, and a state new-drug violation can support a private unfair-trade-practice claim.
To be clear, this doesn't threaten traditional compounding. The court emphasized that pharmacies making tailored medications for patients with real clinical needs — like allergies to an inactive ingredient, inability to swallow the commercial form, or a drug shortage — are protected under state and federal pharmacy law.
ANTITRUST
Compounder’s Antitrust Suit Against Lilly and Novo Dismissed With Prejudice
Judge Micaela Alvarez (W.D. Tex.) threw out Strive Specialties' antitrust lawsuit against Lilly and Novo on August 5 — permanently. The court ruled that compounded and branded GLP-1s aren't interchangeable products, and that Strive was complaining about harm to its own business, not harm to competition.
STATE RULEMAKING / USP
Montana Proposal Would Extend Sterile-Compounding Rules to Out-of-State CSP Operations
Montana Board of Pharmacy MAR Notice No. 2026-131 would require any pharmacy that compounds sterile products — including out-of-state and mail-order operations — to get a sterile-compounding endorsement (no fee) and name a USP <797> designated person. A separate rule would require out-of-state facilities shipping patient-specific meds to Montana patients to hold a mail-order pharmacy license. Comments on both are due Friday, August 21 at 5:00 p.m.
Clinical Trial Watch
What researchers study today is what prescribers ask you to compound tomorrow. Newly registered or updated this week (posted on or after Aug 13, 2026).
Trial | Phase · N · Sponsor | Status | Why it matters |
|---|---|---|---|
Self-applied lidocaine 2.5% / prilocaine 2.5% cream for IUD insertion & endometrial biopsy → | Phase N/A · 174 · Mount Sinai (Canada) | Not yet recruiting | Compounded topical anesthetic in a VersaPro base, studied for patient self-application before office GYN procedures — a demand signal for compounded LET/BLT-class topicals. |
Phase 3 · 450 · Novo Nordisk | Recruiting | Another large oral-GLP-1 program (62 sites); oral formulations reshape the compounded-injectable demand curve. | |
NNC0721-8060 — first-in-human safety / PK, benchmarked against semaglutide → | Phase 1 · 142 · Novo Nordisk | Not yet recruiting | New Novo obesity molecule with semaglutide as the active comparator — an early read on the next pipeline entrant. |
Resistance training vs usual care on thigh muscle volume during tirzepatide → | Phase 4 · 150 · TU Munich | Not yet recruiting | Head-on with GLP-1 muscle loss — the concern behind growing interest in adjunct peptide and amino-acid compounding. |
PK of two cagrilintide presentations in overweight / obesity → | Phase 1 · 50 · Novo Nordisk | Active, not recruiting | Amylin-analog presentation work; cagrilintide's bulk-substance status is one to watch on the 503A list. |
Tirzepatide for menopausal vasomotor symptoms & biological aging → | Phase 4 · 40 · Mayo Clinic | Recruiting | GLP-1 pushed into a menopause indication — a novel-use signal for the prescriber demand you field. |
State & Federal Legislative Tracker
Where the bills and cases stand. Updated weekly.
Measure | Status | What it does |
|---|---|---|
Louisiana Act 374 (SB 253) | Effective August 1 | Permits peptide compounding if the peptide is off the FDA Category 2 list and API is from an FDA-registered manufacturer. |
California AB 1990 | Before the CA Senate (unchanged from Aug 7) | Requires compounded-med ads to carry FDA-approved risk language. APC opposes the labeling provision. |
Virginia HB 917 | In committee (unchanged from Aug 7) | Restricts compounding from bulk drug substances; records to Board within 48 hours of request. |
Colorado SB 66 | Postponed indefinitely | GLP-1 labeling and sourcing requirements. Dead for now. |
SAFE Drugs Act (S. 3794) | Reported to full Senate July 22; awaiting floor vote | Caps "essentially a copy" compounding at 20/month, adds out-of-state reporting, 503B pre-inspection. |
GLP-1 503B Exclusion | Comment closed July 30; awaiting final | Proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Not a final rule. |
PCAC July 23–24 peptides | Advisory votes only; no proposed rule | Six recommended, Emideltide not recommended. 503A list unchanged. |
DEA-1645 DORAs (91 FR 51606) | NPRM published Aug 11; comments due Sept 10 | Proposes moving suvorexant, lemborexant, and daridorexant from Schedule IV to Schedule V. FR → |
✉ That's your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.